

RESEARCH ARTICLE

Assessment of the unified model of performance: accuracy of group-average and individualised alertness predictions

Nikolai V. Priezev^{1,2} | Francisco G. Vital-Lopez^{1,2} | Jaques Reifman¹ 

¹Department of Defense Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, United States Army Medical Research and Development Command, Fort Detrick, Maryland, USA

²The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA

Correspondence

Jaques Reifman, Senior Research Scientist and Director, Department of Defense Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, US Army Medical Research and Development Command, ATTN: FCMR-TT, 504 Scott Street, Fort Detrick, MD 21702-5012, USA.
Email: jaques.reifman.civ@mail.mil

Funding information

US Army Medical Research and Development Command, Grant/Award Number: W81XWH20C0031

Summary

To be effective as a key component of fatigue-management systems, biomathematical models that predict alertness impairment as a function of time of day, sleep history, and caffeine consumption must demonstrate the ability to make accurate predictions across a range of sleep-loss and caffeine schedules. Here, we assessed the ability of the previously reported unified model of performance (UMP) to predict alertness impairment at the group-average and individualised levels in a comprehensive set of 12 studies, including 22 sleep and caffeine conditions, for a total of 301 unique subjects. Given sleep and caffeine schedules, the UMP predicted alertness impairment based on the psychomotor vigilance test (PVT) for the duration of the schedule. To quantify prediction performance, we computed the root mean square error (RMSE) between model predictions and PVT data, and the fraction of measured PVTs that fell within the models' prediction intervals (PIs). For the group-average model predictions, the overall RMSE was 43 ms (range 15–74 ms) and the fraction of PVTs within the PIs was 80% (range 41%–100%). At the individualised level, the UMP could predict alertness for 81% of the subjects, with an overall average RMSE of 64 ms (range 32–147 ms) and fraction of PVTs within the PIs conservatively estimated as 71% (range 41%–100%). Altogether, these results suggest that, for the group-average model and 81% of the individualised models, in three out of four PVT measurements we cannot distinguish between study data and model predictions.

KEYWORDS

alertness prediction model, fatigue, neurobehavioral performance, psychomotor vigilance test, sleep deprivation

INTRODUCTION

Public and private sectors can use biomathematical fatigue models to help design, compare, and contrast work schedules for teams of workers as well as to provide individualised guidance for optimising the use of fatigue countermeasures (Integrated Safety Support, 2022; Powell, Spencer, & Petrie, 2014; Reifman et al., 2019, 2022; Vital-Lopez, Doty, & Reifman, 2021). As may be

expected, decision-makers and users of such fatigue-management tools generally assume that the underlying mathematical models driving these tools have been well validated and peer-reviewed before they come to market or become publicly available. However, the opposite more closely reflects common practice.

Over the last decade, only two studies have performed side-by-side comparisons among multiple biomathematical fatigue-prediction models (Flynn-Evans et al., 2020; Hilaire et al., 2017). While such

analyses are invaluable, especially if performed by independent reviewers, these studies compared and contrasted the models against a single study condition, which is insufficient to gauge model performance across a broad range of sleep/rest schedules reflective of everyday life, for which the tools are expected to be used. One exception is the work of Powell et al. (2014), which attempted to validate the System for Aircrew Fatigue Evaluation model for 11 distinct commercial flight operations. Unfortunately, as detailed by the authors, a number of simplifying assumptions regarding the inputs to the model may have contributed to the low agreement between model predictions and recorded quantitative measures of fatigue. In addition, because this model does not account for fatigue countermeasures, their assessment did not consider the beneficial effects of caffeine, the most widely used stimulant compound consumed daily by ~85% of the US population (Mitchell, Knight, Hockenberry, Teplansky, & Hartman, 2014).

Over the past 15 years, our group at the US Army has been incrementally developing and enhancing the unified model of performance (UMP), which predicts alertness impairment, as determined by the psychomotor vigilance test (PVT), at the group and individual levels, as a function of sleep history, time of day, and caffeine consumption (Liu, Ramakrishnan, Laxminarayan, Balkin, & Reifman, 2017; Rajdev et al., 2013; Ramakrishnan et al., 2016b; Ramakrishnan, Wesensten, Balkin, & Reifman, 2016a). As we enhanced the UMP over time, we continually validated the model predictions using an array of total sleep deprivation (TSD) and chronic sleep restriction (CSR) conditions (Ramakrishnan, Wesensten, Balkin, & Reifman, 2016a), as well as a diverse set of caffeine-consumption schedules (Ramakrishnan, Wesensten, Kamimori, et al., 2016b). However, we described such model validations in different reports, sometimes with slight changes in the model or model parameter values, involving a limited number of conditions. As we have now completed model enhancements and frozen the model, culminating in the development of the Web- and smartphone-based *2B-Alert* tools (Reifman et al., 2019; Reifman et al., 2022), we sought to perform a thorough validation of the UMP. To this end, we assessed its ability to predict alertness impairment at the group-average level and at the individual-specific level across a broad range of sleep and caffeine schedules (22 from 12 different studies), involving a total of 301 unique subjects (244 at the individual level). Given two inputs (sleep and caffeine schedules), the UMP predicted alertness impairment, as measured by the mean response time (RT) in the PVT. To assess prediction performance at the group-average level, we used two metrics: the root mean square error (RMSE) between the model predictions and the group-average PVT data and the fraction of the data that fell within the prediction intervals (PIs) of the model. Similarly, to assess the prediction performance at the individual level, we computed these two metrics using the corresponding individual-specific model predictions and the individuals' PVT data. We used the fraction of the PVT data that fell within the PIs of the models to estimate the extent to which the UMP predictions were indistinguishable from the PVT measurements.

METHODS

Datasets for assessment of model performance

To validate the group-average and individualised models, we used the mean RT in the PVT as a measure of alertness impairment collected from 12 studies (V1–V12). These involved a total of 301 unique subjects and 22 diverse conditions, including 14 distinct sleep schedules and seven caffeine conditions. Table 1 provides a brief description of the 22 study conditions, including the participant's sex, PVT duration and number collected in each condition, sleep schedule, including baseline, type of sleep challenge, and recovery, as well as caffeine-consumption schedule. The sleep schedules typically included several baseline days with either habitual sleep (7–8 h of time in bed [TIB]) or extended sleep (10 h of TIB), a sleep challenge period involving either CSR, TSD, or both, and a recovery phase of 8–24 h of TIB, for 1–5 consecutive nights. The studies reflect PVT data collected in both laboratory (V1–V5, V7, and V10–V12) and field (V6, V8, and V9) conditions, with three studies (V1, V3, and V8) using a cross-over design, in which the same subject performed PVTs under two different sleep or caffeine conditions. At different stages of model development throughout the years, we did use data from three of the 12 studies (V3, V7, and V12) to develop or optimise earlier versions of the models developed at those times (Liu et al., 2017; Rajdev et al., 2013; Ramakrishnan et al., 2013). As described below, the actual parameter values of the group-average model validated herein were derived using data from two different, earlier studies.

Unified Model of Performance

Based on the two-process model postulated by Borbély and Achermann (1999), we previously developed the UMP to predict the temporal patterns of alertness for conditions ranging from CSR to TSD challenges (Rajdev et al., 2013), extending the two-process model in three ways. First, by taking into account prior sleep–wake history, the UMP modulates alertness impairment and recovery as a function of sleep debt, leading to a relatively slow decrease in impairment rates after extended sleep, i.e., sleep banking (Rupp, Wesensten, Bliese, & Balkin, 2009), and slow recovery rates after CSR. Second, the UMP accounts for the alertness-enhancing effects of caffeine by assuming that it has a multiplicative effect on alertness throughout the sleep–wake cycle (Ramakrishnan, Wesensten, Kamimori, et al., 2016b). That is, the UMP predicts alertness impairment $P(t)$ at time t after consumption of caffeine dose c , as follows:

$$P(t) = P_0(t) \times g_{PD}(t, c), \quad (1)$$

where $P_0(t)$ represents the alertness impairment predicted at time t in the absence of caffeine and $g_{PD}(t, c)$ denotes the pharmacodynamic (PD) effect of caffeine, which varies from 0 to 1, where the upper bound 1 corresponds to PD effects in the absence of caffeine and the

TABLE 1 Summary of studies used to assess the unified model of performance

Study condition	Number of subjects (men)	PVTs, N	Sleep schedule			Caffeine-consumption schedule	
			Baseline (TIB, h)	TSD (wakefulness, h) or CSR (TIB, h)	Recovery (TIB, h)	Dose, mg	Time of day
Studies with no caffeine							
V1a	36 (18)	61	2 nights (8) + 7 nights (10)	TSD (39)	—		
V1b	36 (18)	62	2 nights (8)	7 CSR nights (6) + TSD (41)	—		
V2a ^a	12 (7)	143	8 nights (10)	7 CSR nights (3)	5 nights (8)		
V2b ^a	12 (4)	143	8 nights (8)	7 CSR nights (3)	5 nights (8)		
V3a	19 (11)	109	7 nights (10)	7 CSR nights (3)	3 nights (8)		
V3b	19 (11)	64	7 nights (10)	TSD (63)	3 nights (8)		
V4	12 (12)	45	-	TSD (25) + 4 CSR day (4)	—		
V5 ^a	21 (14)	23	1 night (8)	TSD (62)	1 night (12)		
Studies with caffeine and placebo							
V6a ^a	11 (11)	35	1 night (8)	TSD (31) + 2 CSR days (4)	—		
V6b ^a	10 (10)	35	1 night (8)	TSD (31) + 2 CSR days (4)	—	4 × 200	9:45 p.m., 1:00 a.m., 3:45 a.m., 7:00 a.m. (daily)
V7a ^a	14 ^b	34	1 night (8)	TSD (61)	1 night (12)		
V7b ^a	11 ^b	34	1 night (8)	TSD (61)	1 night (12)	1 × 600	After 44 h of wakefulness at 3:00 a.m.
V8a ^a	21 ^b	11	1 night (8)	TSD (28)	—		
V8b ^a	21 ^b	11	1 night (8)	TSD (28)	—	1 × 400, 2 × 200	9:30 p.m., 3:00 a.m., 5:00 a.m. during TSD
V9a ^a	15 (15)	31	—	1 CSR night (3) + TSD (33)	—		
V9b ^a	15 (15)	31	—	1 CSR night (3) + TSD (33)	—	2 × (100, 200)	9:45 p.m., 11:45 p.m., 1:45 a.m., 3:45 a.m. during TSD
V10a	24 (10)	145	5 nights (10)	5 CSR nights (5)	3 nights (8)		
V10b	24 (9)	145	5 nights (10)	5 CSR nights (5)	3 nights (8)	2 × 200	8:00 a.m., 12:00 p.m. (daily)
V11a	10 (6)	37	1 night (7)	TSD (54.5)	1 night (24)		
V11b	10 (6)	37	1 night (7)	TSD (54.5)	1 night (24)	1 × 600	After 41.5 h of wakefulness at 11:50 p.m.
V12a	12 (11)	48	1 night (8)	TSD (85)	1 night (12)		
V12b	12 (11)	48	1 night (8)	TSD (85)	1 night (12)	1 × 600	After 65 h of wakefulness at 12:00 a.m.

References: V1 (Lo et al., 2012), V2 (Rupp et al., 2009), V3 (Rupp et al., 2012), V4 (Wesensten, Reichardt, & Balkin, 2007), V5 (Reifman et al., 2019), V6 (Kamimori et al., 2015), V7 (Killgore et al., 2008), V8 (McLellan, Bell, & Kamimori, 2004), V9 (McLellan et al., 2005), V10 (So, Quartana, & Ratcliffe, 2016), V11 (Wesensten, Belenky, Thorne, Kautz, & Balkin, 2004), and V12 (Wesensten, Killgore, & Balkin, 2005).

CSR, chronic sleep restriction; TIB, time in bed; TSD, total sleep deprivation.

^a5-min psychomotor vigilance test (PVT); otherwise, 10-min PVT.

^bSex information was not available.

TABLE 2 Equations of the unified model of performance**UMP governing equations**

Performance impairment without caffeine (P_o):

$$P_o(t, \theta) = S(t) + \kappa C(t), \quad (2)$$

where θ represents the eight model parameters of the UMP, namely, $\theta = [U, \tau_w, \tau_s, \tau_{LA}, \kappa, \phi, S_0, L_0]^T$ as defined below. The time-dependent functions $S(t)$ and $C(t)$ denote the homeostatic and circadian processes, respectively, and κ denotes the circadian amplitude. Because the UMP predictions are not particularly sensitive to time constants τ_w , τ_s , and τ_{LA} (Ramakrishnan et al., 2015), we fixed them to 18.2 h, 4.2 h, and 7.0 days, respectively.

Circadian process (C):

$$C(t) = \sum_{j=1}^5 a_j \sin[j \frac{2\pi}{\tau} (t + \phi)], \quad (3)$$

where a_j , $j = 1, \dots, 5$, denotes the amplitude of the five harmonics ($a_1 = 0.97$, $a_2 = 0.22$, $a_3 = 0.07$, $a_4 = 0.03$, and $a_5 = 0.001$), τ indicates the fundamental period of the circadian clock (~24 h), and ϕ represents the circadian phase.

Homeostatic process (S):

$$\dot{S}(t) = \begin{cases} 1/\tau_w [U - S(t)] & \text{during wakefulness} \\ -1/\tau_s [S(t) - L(t)] & \text{during sleep,} \end{cases} \quad (4)$$

where U and L denote the upper and lower asymptotes, respectively, and τ_w and τ_s indicate the wake and sleep time constants of the increasing and decreasing sleep pressure, respectively. $S(0) = S_0$ and $L(0) = L_0$ correspond to the initial-state values for S and L .

Lower asymptote (L) of process S is defined as follows:

$$L(t) = \begin{cases} \max\{U - (U - L_0)\exp(-t/\tau_{LA}), -0.11U\} & \text{during wakefulness} \\ \max\{-2U + (2U + L_0)\exp(-t/\tau_{LA}), -0.11U\} & \text{during sleep,} \end{cases} \quad (5)$$

where τ_{LA} denotes the time constant of the exponential decay of the effect of sleep history on performance.

The effect of caffeine (g_{PD}):

$$g_{PD}(t, c) = \left[1 + M_c \frac{k_a}{k_a - k_c} \{ \exp[-k_c(t - t_o)] - \exp[-k_a(t - t_o)] \} \right]^{-1} \text{ for } t \geq t_o \quad (6)$$

$M_c = M_o \cdot c$ and $k_c = k_o \exp(-z \cdot c)$,

where M_c and k_c indicate the amplitude factor and the elimination rate for a caffeine dose c scheduled at time t_o , respectively. Here, M_o , k_o , z , and k_a denote the amplitude slope, basal elimination rate, decay constant, and absorption rate, respectively. We fixed the caffeine parameters as described in Table S1.

UMP, unified model of performance.

theoretical lower bound 0 represents the maximal PD effect on alertness impairment. In this formulation, the effect of caffeine is greater when the alertness impairment is higher, in accordance with experimental studies (Landolt, Retey, & Adam, 2012; Rétey, Adam, Gottselig, et al., 2006). Table 2 shows the UMP equations governing the caffeine-free portion of the model [$P_o(t)$] in Equations (2–5) and the caffeine effect [$g_{PD}(t, c)$] in Equation (6). Overall, the UMP has a total of 12 model parameters, eight for the caffeine-free portion of the model, which we obtained by fitting the parameters to the group-average PVT data in the study by Belenky et al. (2003), and four to represent the effects of caffeine (Ramakrishnan, Wesensten, Kamimori, et al., 2016b), which we obtained by fitting the caffeine parameters to the group-average PVT data in the study by Kamimori, Johnson, Thorne, and Belenky (2005). Table S1 shows all parameter values for the group-average model (see Supporting Information).

Third, in addition to predicting the average alertness of a collection of individuals in a “group-average” model, the UMP can be customised to predict alertness impairment of a specific individual in an “individualised” model (Ramakrishnan et al., 2015; Reifman et al., 2019). We develop an individualised model for a subject by customising the model parameters of the caffeine-free portion of the

UMP so that they reflect the subject's response to sleep deprivation measured by the PVT (Liu et al., 2017). Model customisation starts by assuming that the subject has an average response to sleep deprivation and, initially, can be represented by the parameters of the group-average model. Then, after each PVT, we customise the model by recursively adjusting its parameters using a Bayesian-learning approach, where we balance the weight of the latest PVT measurement (second term in Equation (7) in Table 3) against that of the group-average model (i.e., the prior, the first term in Equation (7)). As the number of PVT measurements increases, the weight of the latest PVT increases, leading to an individualised model that represents the individual's sleep-loss phenotype (Liu et al., 2017). The model parameters are recursively updated after each PVT by solving two algebraic equations (Equations (8) and (9) in Table 3), where only five UMP parameters (Table 2) need to be customised (Ramakrishnan et al., 2015).

Learning an individual's sleep-loss trait

To determine whether the UMP recursively learned an individual's sleep-loss trait after n PVTs, we computed the difference between RMSEs of a recursively learned model and the best-fit model:

TABLE 3 Individualisation of the unified model of performance**Bayesian learning:**

$$\arg \min_{\theta} \left\{ (\theta - \theta_0)^T \Sigma_0^{-1} (\theta - \theta_0) + \frac{1}{\sigma^2} \sum_{i=1}^n [y_i - P_o(t_i, \theta)]^2 \right\}, \quad (7)$$

where θ_0 represents the parameters of an “average” individual, Σ_0 denotes the prior variance-covariance matrix of the model parameters θ_0 , and σ^2 indicates the noise variance in PVT measurements y_i . The solution of Equation (7) leads to the individualised model based on a set of n PVT measurements y_i , with $i = 1, 2, \dots, n$, up to the current time t_n (where $n \leq N$, the total number of measurements).

Recursive learning based on the extended Kalman filter: We recursively estimated the model parameter $\hat{\theta}_n$, at the current time t_n , with $n = 1, 2, \dots, N$, as a function of the previous estimate $\hat{\theta}_{n-1}$ at time t_{n-1} and the current PVT measurement y_n , by solving the following algebraic equations:

$$\hat{\theta}_n = \hat{\theta}_{n-1} + \frac{\hat{\Sigma}_{n-1} J_n^T}{\sigma^2 + J_n^T \hat{\Sigma}_{n-1} J_n} [y_n - P_o(t_n, \hat{\theta}_{n-1})] \quad (8)$$

$$\hat{\Sigma}_n = \left(I - \frac{\hat{\Sigma}_{n-1} J_n^T J_n}{\sigma^2 + J_n^T \hat{\Sigma}_{n-1} J_n} \right) \hat{\Sigma}_{n-1} \quad (9)$$

where $\hat{\Sigma}_n$ and $\hat{\Sigma}_{n-1}$ represent the estimated variance-covariance matrices of the model parameters at times t_n and t_{n-1} , respectively, $J_n = \partial P_o(t_n, \theta) / \partial \theta|_{\theta=\hat{\theta}_{n-1}}$ denotes the Jacobian of the model output with respect to the model parameters at time t_n , and I represents the identity matrix. To start the recursion, we assume that $\hat{\theta}_0 = \theta_0$ and $\hat{\Sigma}_0 = \Sigma_0$, where θ_0 and Σ_0 denote priors as in Equation (7). To customise the model to an individual, we only needed to estimate five UMP parameters, i.e., the upper asymptote U , the circadian amplitude and phase, κ and ϕ , respectively, and the initial state values for process S and for the lower asymptote L_0 (Table S1).

PVT, psychomotor vigilance test; UMP, unified model of performance.

$$\Delta \text{RMSE}_n = \sqrt{\frac{1}{N} \sum_{i=1}^N [y_i - P_o(t_i, \hat{\theta}_n)]^2} - \sqrt{\frac{1}{N} \sum_{i=1}^N [y_i - P_o(t_i, \theta^*)]^2}, \quad (10)$$

where y_i , $i = 1, 2, \dots, n, \dots, N$, represents the complete set of N PVTs, $\hat{\theta}_n$ denotes the recursively estimated model parameters after n PVTs, and θ^* indicates the parameters of the best-fit model, defined as the solution of Equation (7) obtained using all N PVTs of an individual, for the corresponding study condition. We assumed that the model “learned” the sleep traits of an individual after n PVTs when ΔRMSE_n reached and remained < 5 ms with increasing numbers of PVTs. This arbitrary threshold guaranteed near-optimal predictions, while retaining sufficient remaining PVTs (10% of N or five, whichever was smaller) to independently assess the goodness of the learned model to predict an individual's trait.

In addition, we assessed the ability of the individualised model to learn a subject's sleep-loss trait with a reduced set of PVT measurements. For this analysis, we focused on the five CSR study conditions of 3 h (V2a, V2b, and V3a), 5 h (V10a), and 6 h (V1b) of sleep/night in Table 1, because they more closely resembled everyday sleep-deprivation conditions and provided a sufficient number of PVTs to train the individualised models (at least 5 consecutive CSR

nights). We did not consider CSR conditions with caffeine consumption to reduce potential confounding factors. For the selected study conditions, we obtained an individualised model for each subject using a subset of the available PVT measurements and compared the performance of these models with those of the corresponding best-fit models.

Assessment of model performance

To assess the performance of the group-average model predictions for each study condition, we used two metrics. First, we calculated the RMSE between the model-predicted alertness impairment $P(t)$ in Equation (1) and the mean PVT for each session. Second, we estimated PIs around $P(t)$ and computed the fraction of PVT data that fell within the PIs. For the group-average predictions, we defined PI_j for PVT session j in a study condition, as follows:

$$PI_j = P_j(t) \pm z \sqrt{\sigma_{fit}^2 + \sigma_{scj}^2}, \quad (11)$$

where $P_j(t)$ denotes the group-average model prediction for PVT session j , z (~ 1.96) represents the standard score for 95% confidence level, and the uncertainty term comprises two components: the standard deviation ($\sigma_{fit} = 26$ ms) in the PVT data of the study used to estimate the parameters of the group-average model (Belenky et al., 2003) and the standard deviation of the mean PVT (σ_{scj}) in session j , for the study condition we wish to predict. This definition of PI is more stringent than the alternative of separately computing PIs for the model prediction (based on σ_{fit}) and for the PVT data (based on σ_{scj}) and determining if they overlap (because $(\sigma_{fit}^2 + \sigma_{scj}^2)^{1/2} < (\sigma_{fit} + \sigma_{scj})$).

To assess the performance of the individualised model predictions, for each of the 301 unique subjects across the 22 study conditions, we first determined whether the subject's individualised model was capable of learning the subject's sleep-loss trait using a subset of the study-condition data. We labelled a subject as “learnable” if the model predictions for the subject satisfied two arbitrary criteria: (i) the percentage of PVT measurements that fell within the PIs of the individualised model predictions using the total number of measurements for the subject was $> 50\%$ and (ii) after learning a subject using a subset of the study-condition data, there were sufficient remaining PVT measurements to assess the performance of the model predictions (at least five PVTs or 10% of the total number of PVT measurements in the study condition). Subjects who did not meet these criteria were labelled as “not-learnable.” The first criterion speaks to the variance in the data. If the variance is too large (i.e., the PVT measurements have too much variability), given the limited number of adjustable parameters in the model, it does not have sufficient degrees of freedom to capture the sleep-loss trait of the subject. This criterion attempts to capture the fact that even if we were to use *all* PVT measurements in the study condition to *fit* the model to the data, it would still be an inadequate model because $> 50\%$ of the data were not within the PIs. Notably, our analyses

TABLE 4 Performance of the group-average model and the individualised model. The values for the individualised models denote their mean (range) performance in each study condition for the psychomotor vigilance tests after the model had “learned” the subject’s trait-like response to sleep deprivation

			Group-average model ^c		Individualised model ^d , mean (range)			
Study condition	Number of subjects (learnable subjects)	Total PVTs ^a , N	RMSE, ms	Fraction ^b , %	PVTs to learn a subject, n	Time to learn a subject, h ^e	RMSE, ms	Fraction ^b , %
Caffeine free								
V1a TSD	36 (12)	61 (43, 18, 0)	46	79	45 (1–59)	196 (0–245)	83 (41–229)	47 (0–88)
V1b both ^f	36 (12)	62 (43, 19, 0)	28	100	41 (4–60)	183 (18–245)	101 (25–231)	56 (0–93)
V2a CSR	12 (12)	143 (0, 88, 55)	38	69	48 (8–86)	99 (7–176)	56 (26–109)	86 (57–100)
V2b CSR	12 (10)	143 (0, 88, 55)	26	100	41 (15–96)	85 (27–199)	54 (20–118)	87 (65–100)
V3a CSR	19 (17)	109 (13, 76, 20)	70	41	45 (23–76)	221 (52–305)	57 (21–90)	72 (45–100)
V3b TSD	19 (17)	64 (13, 31, 20)	74	70	33 (25–47)	195 (177–227)	58 (26–79)	72 (47–100)
V4 both	12 (11)	45 (0, 45, 0)	60	80	24 (12–36)	48 (22–75)	39 (18–61)	87 (65–100)
V5 TSD	21 (20)	23 (0, 20, 3)	25	83	12 (7–19)	33 (18–54)	41 (17–95)	87 (50–100)
Placebo								
V6a both	11 (11)	35 (4, 31, 0)	55	63	17 (11–32)	56 (41–89)	46 (21–103)	81 (17–100)
V7a TSD	14 (13)	34 (0, 30, 4)	30	82	14 (1–26)	26 (0–54)	60 (26–179)	82 (42–100)
V8a TSD	21 (17)	11 (0, 11, 0)	15	82	9 (3–11)	23 (5–28)	66 (15–179)	57 (0–100)
V9a both	15 (6)	31 (0, 31, 0)	54	87	13 (8–17)	38 (34–42)	85 (22–309)	64 (0–100)
V10a CSR	24 (24)	145 (0, 105, 40)	29	97	53 (12–121)	68 (12–168)	48 (23–109)	83 (27–100)
V11a TSD	10 (9)	37 (3, 31, 1)	54	89	26 (18–32)	53 (40–60)	147 (53–267)	32 (17–68)
V12a TSD	12 (10)	48 (2, 42, 4)	73	63	29 (14–39)	63 (34–84)	78 (37–139)	60 (38–85)
Caffeine								
V6b both	10 (10)	35 (4, 31, 0)	47	63	13 (8–16)	45 (38–53)	32 (18–62)	91 (64–100)
V7b TSD	11 (11)	34 (0, 30, 4)	31	79	19 (11–28)	37 (20–54)	47 (27–73)	80 (50–100)
V8b TSD	21 (17)	11 (0, 11, 0)	22	100	9 (3–11)	23 (5–28)	41 (16–83)	90 (0–100)
V9b both	15 (13)	31 (0, 31, 0)	44	74	9 (1–16)	27 (0–41)	53 (17–115)	75 (0–100)
V10b CSR	24 (23)	145 (0, 105, 40)	19	100	36 (1–105)	44 (0–135)	50 (30–98)	80 (43–98)
V11b TSD	10 (6)	37 (3, 31, 1)	51	76	33 (29–35)	61 (57–63)	105 (68–147)	33 (0–67)

TABLE 4 (Continued)

Study condition	Number of subjects (learnable subjects)	Total PVTs ^a , N	Group-average model ^c		Individualised model ^d , mean (range)			
			RMSE, ms	Fraction ^b , %	PVTs to learn a subject, n	Time to learn a subject, h ^e	RMSE, ms	Fraction ^b , %
V12b TSD	12 (9)	48 (2, 42, 4)	64	75	21 (13–30)	48 (32–66)	69 (49–87)	61 (50–82)
Average			43	80	27	76	64	71

References: V1 (Lo et al., 2012), V2 (Rupp et al., 2009), V3 (Rupp et al., 2012), V4 (Wesensten et al., 2007), V5 (Reifman et al., 2019), V6 (Kamimori et al., 2015), V7 (Killgore et al., 2008), V8 (McLellan et al., 2004), V9 (McLellan et al., 2005), V10 (So et al., 2016), V11 (Wesensten et al., 2004), and V12 (Wesensten et al., 2005).

CSR, chronic sleep restriction; PVT, psychomotor vigilance test; RMSE, root mean square error between the model prediction and the measured PVT data; TSD, total sleep deprivation.

^aThe total number of PVTs and the number of PVTs during baseline, sleep challenge, and recovery phases, respectively (see Table 1).

^bFraction is defined as the number of PVTs that fall within the prediction intervals of the model, divided by the total number of PVTs in the study condition (see Methods).

^cBased on 301 unique subjects.

^dBased on 244 unique subjects.

^eTime between the first and last PVT sessions required to learn the sleep-loss trait of a subject.

^fBoth represents study conditions that included CSR and TSD challenges.

included *all* reported data from each study, even though we observed obvious outliers in a number of subjects across the studies. The second criterion is to guarantee that we have sufficient PVT measurements not used in model training to assess the performance of the model predictions. For the cross-over design studies, we required these conditions be met for both arms of the study for a subject to be labelled as learnable.

For the individualised models that met these criteria, we assessed their performance using equivalent metrics as in the group-average case. Using the PVT data for the sessions *after* the model had learned the subject's trait, we computed the RMSE between the model-predicted alertness impairment $P(t)$ in Equation (1) and the subject's measured PVT and calculated the fraction of the PVT data that fell within the PIs. For each subject, we defined PI_j for each PVT session j in each study condition, as follows:

$$PI_j = P_j(t) \pm z \sigma_{ws}, \quad (12)$$

where $P_j(t)$ denotes the individualised prediction for the j PVT session, $z = 1.96$ as above, and σ_{ws} denotes the variance of the PVT data upon repeated measurements by the same subject under the same condition, i.e., a measure of within-subject variability. In the absence of repeated data, to err on the side of caution, we assumed σ_{ws} to be ~30 ms (Khitrov et al., 2014) for all subjects in all study conditions. This is a conservative estimate of σ_{ws} because it was obtained for subjects under well-rested conditions and σ_{ws} is known to be larger under sleep-loss conditions (Rupp, Wesensten, & Balkin, 2012). For both the group-average and the individualised model predictions, the larger the fraction of PVT data laying within the corresponding PI, the higher the accuracy of the UMP prediction.

Importantly, choosing a sufficiently wide PI can artificially inflate the number of predictions that fall within the interval, making it an

inappropriate metric of performance. Precisely for this very same reason, by design, the PIs we used in our analyses were based *solely* on the underlying variability of the PVT data, rather than on the uncertainty of the model predictions. For example, for the group-average predictions, in addition to the variability in the data used to develop the model, the width of the PI depended on the variability of the study-condition data we wished to predict. Hence, if the measured PVT data in the study we wished to predict had large variability, then the PIs would be wider, as one would expect. In fact, had we designed a new study to reproduce the original experimental study, we would expect the results to fall within these very same PIs with a 95% confidence level.

We estimated the parameters for the group-average model using 10-min PVT data. Thus, for study conditions that used a 10-min PVT, we directly compared the group-average or individualised predictions with the data. For study conditions that used a 5-min PVT (marked with a superscript "a" in the first column in Table 1), we first obtained predictions for the 10-min PVT, converted the 10-min PVT predictions into an equivalent 5-min PVT prediction using an affine transformation (Hastie, Tibshirani, & Friedman, 2001), and then compared the equivalent 5-min PVT predictions with the 5-min PVT data. The individualised models required an additional pre-processing step, where we first transformed the 5-min PVT data into 10-min PVT data, using the inverse affine transformation, before performing the steps above. We refer the reader to the Supporting Information for a detailed description of the affine transformation. In addition, we observed between-study differences in the PVT data across the study conditions. To normalise these differences, we added a constant value δ to the group-average predictions for each study condition, where δ was computed as the average difference between UMP predictions and PVT data within the first 16 h of wakefulness on the first day of the sleep-deprivation challenge (Ramakrishnan, Wesensten, Balkin, & Reifman, 2016a).




FIGURE 1 Psychomotor vigilance test (PVT) mean response time (RT) data along with the group-average and individualised model predictions for study condition V1b. The study consisted of 2 baseline nights of 8 h of time in bed (TIB; for B1 and B2), followed by 7 nights of chronic sleep restriction (CSR; 6 h of TIB for C1–C7) and 41 h of total sleep deprivation (TSD; T1). (a) Group-average mean RT and group-average model predictions, representative of above-average model performance. The error bars denote two standard errors of the mean. (b–d) Individualised predictions for three subjects: subject #20, strong individualised model predictions (b); subject #14, average individualised model predictions (c); and subject #13, weak individualised model predictions (d). Open and filled circles correspond to data used by the individualised model to “learn” the subject and assess model predictions, respectively. The shaded regions in all panels represent the width of the prediction intervals. The grey vertical stripes represent sleep episodes. RMSE, root mean square error

RESULTS

We validated the group-average and individualised models by comparing their predictions against measured PVT data in the 12 studies (V1–V12). Table 4 summarises the prediction performance for the 301 unique subjects under the 22 different sleep and caffeine-consumption conditions described in Table 1. Overall, the group-average model predictions demonstrated that the UMP captured the alertness impairment at the population level

for a wide range of sleep and caffeine conditions, with an average RMSE between the UMP predictions and the PVT data of 43 ms, ranging from 15 ms in study condition V8a to 74 ms in V3b. Importantly, 80% of the predictions fell within the PI in Equation (11), suggesting that the majority of the group-average predictions were indistinguishable from the mean of the observed PVT measurements. This fraction ranged from 63% (V6a, V12a, and V6b) to 100% in four study conditions (V1b, V2b, V8b, and V10b), except for study V3a (41%).




FIGURE 2 Psychomotor vigilance test (PVT) mean response time (RT) data along with the group-average and individualised model predictions for study condition V11b. The study consisted of 1 baseline night (B1) of 7 h of time in bed (TIB), followed by 54.5 h of total sleep deprivation (TSD; T1 and T2), where subjects consumed 600 mg of caffeine (vertical dashed green line) at 11:50 p.m. (i.e., after 41.5 h of wakefulness). (a) Group-average mean RT and group-average model predictions, representative of below-average model performance. The error bars denote two standard errors of the mean. (b–d) Individualised predictions for three subjects: subject #10, average individualised model predictions (b); subject #3, weak individualised model predictions (c); and subject #9, weak individualised model predictions (d). Open and filled circles correspond to data used by the individualised model to “learn” the subject and assess model predictions, respectively. The shaded regions in all panels represent the width of the prediction intervals. The grey vertical stripes represent sleep episodes. RMSE, root mean square error

Table 4 also shows the prediction performance of the individualised model for 244 unique subjects (out of 301) who were learnable (i.e., had >50% of PVT data within the PIs) and had a sufficient number of PVTs (at least five or 10% of N) for independent assessment after the model had learned the subject's trait. Of the 57 (301 minus 244) not-learnable subjects, 42 did not meet the

50% criterion and 15 did not have a sufficient number of PVTs for model assessment (see Methods). Overall, the individualised models captured the alertness-impairment levels with varying accuracy, with RMSEs ranging from 32 ms in study condition V6b to 147 ms in V11a, for an average prediction error of 64 ms and 71% of the predictions falling within the PI in Equation (12). Importantly, our analyses




FIGURE 3 Psychomotor vigilance test (PVT) mean response time (RT) data along with the group-average and individualised model predictions for study condition V2b. The study consisted of 8 baseline nights of 8 h of time in bed (TIB; for B1–B8), followed by 7 nights of chronic sleep restriction (CSR; 3 h of TIB for C1–C7) and 5 recovery nights of 8 h of TIB (R1–R5). (a) Group-average mean RT and group-average model predictions, representative of above-average model performance. The error bars denote two standard errors of the mean. (b–d) Individualised predictions for three subjects: subject #11, strong individualised model predictions (b); subject #3, strong individualised model predictions (c); and subject #12, weak individualised model predictions (d). Open and filled circles correspond to data used by the individualised model to “learn” the subject and assess model predictions, respectively. The shaded regions in all panels represent the width of the prediction intervals. The grey vertical stripes represent sleep episodes. RMSE, root mean square error

included *all* PVT data for each subject, regardless of how inaccurate they seemed, including obvious outliers.

We also computed the number of PVTs required by the individualised model to learn an individual's trait-like response to sleep deprivation and caffeine consumption for the same 22 conditions. Table 4 shows that the average number of PVTs needed to individualise the model parameters was 27, with 25% of the models requiring up to 33% of the data to learn a subject and 75% requiring up to 80% of the data. Overall, the number of PVTs required for the model

to learn a subject depended on the study condition and varied between subjects.

Figures 1–4 show the observed PVT mean RT data along with the group-average and individualised model predictions for four study conditions that included CSR and TSD sleep challenges, with and without caffeine. Figure 1 shows the results for the CSR plus TSD challenge in study condition V1b (Table 1), consisting of two baseline nights of 8 h of TIB per night, 7 nights of 6 h of TIB per night, followed by 41 h of TSD. Figure 1a shows the group-average data




FIGURE 4 Psychomotor vigilance test (PVT) mean response time (RT) data along with the group-average and individualised model predictions for study condition V10b. The study consisted of 5 baseline nights (B1–B5) of 10 h of time in bed (TIB), followed by 5 nights of chronic sleep restriction (CSR; 5 h of TIB for C1–C5) and 3 recovery nights of 8 h of TIB (R1–R3). During the CSR phase, subjects consumed 200 mg of caffeine at 8:00 a.m. and 12:00 p.m. (noon) daily (vertical dashed green lines). (a) Group-average mean RT and group-average model predictions, representative of above-average model performance. The error bars denote two standard errors of the mean. (b–d) Individualised predictions for three subjects: subject #6, strong individualised model predictions (b); subject #21, strong individualised model predictions (c); and subject #8, weak individualised model predictions (d). Open and filled circles correspond to data used by the individualised model to “learn” the subject and assess model predictions, respectively. The shaded regions in all panels represent the width of the prediction intervals. The grey vertical stripes represent sleep episodes. RMSE, root mean square error

and corresponding model predictions, where the model yielded very accurate predictions with a RMSE of 28 ms and 100% of the experimental data falling within the Pls. Figure 1b–d show the PVT data and individualised model predictions for three subjects in V1b with distinct sleep-loss phenotypes and model-prediction accuracies. The mean RT data for subject #20 showed negligible variation and consistently low alertness impairment throughout the multiple phases of the study, suggesting that this subject was resilient to sleep deprivation. The individualised model learned this subject by CSR day C3,

after 19 PVTs (open circles, Figure 1b), and accurately predicted alertness impairment throughout the remaining CSR days and TSD challenge (filled circles, RMSE = 37 ms and fraction = 93%). In contrast, subject #13 showed considerable PVT variability over the last day of the TSD challenge (T1, Figure 1d). It took 50 PVTs for the individualised model to learn this subject (open circles), and the predictions that followed yielded a large RMSE (231 ms) with none of the data (filled circles) falling within the Pls. Note that the data showed clear outliers on day T1.

Figure 2 shows the mean RT data as well as the group-average and individualised model predictions for study condition V11b, consisting of 1 baseline night of 7 h of TIB followed by 54.5 h of TSD, with a single 600-mg dose of caffeine at 11:50 p.m. after 41.5 h into the challenge. In this case, the group-average model predictions in Figure 2a yielded results slightly worse than the average model performance over the 22 conditions (RMSE 51 versus 43 ms and fraction 76% versus 80%). As expected, alertness impairment temporarily improved immediately after caffeine consumption at the end of challenge day T1, and the model accurately captured this behaviour. Figure 2b–d show the results for three subjects where the individualised model learned each subject on challenge day T2 after caffeine consumption (open circles), yielding varying degrees of accuracy (RMSE from 68 to 103 ms and fraction from 50% to 20%). The individualised model learned subject #10 slightly faster and more accurately than the other two subjects, who were more vulnerable (#3) or whose data showed greater variability (#3 and #9).

Figure 3 shows the mean RT data and model predictions for study condition V2b, which consisted of 8 baseline nights with 8 h of TIB and a CSR phase with 3 h of TIB for 7 nights, followed by a recovery phase of 8 h of TIB for 5 nights. In this case, the group-average model predictions agreed very well with the experimental data (RMSE 26 ms and fraction 100%, Figure 3a). Figure 3b–d illustrate the effect of PVT variability in the model's ability to learn a subject's trait and its prediction accuracy, for three subjects in this study. The PVT data for subject #11 showed minor changes from day to day and little variability, resulting in quick model learning after only 19 PVTs by CSR day C2 and excellent predictions thereafter (Figure 3b). In contrast, the data for subjects #3 and #12 showed more variability, resulting in a larger number of PVTs to learn the subjects' traits and, for subject #12, yielding a relatively low prediction accuracy (RMSE 118 ms and fraction 65%, Figure 3d), likely due to the large amount of scatter in the PVT data during the last 3 days of CSR and the first recovery day, including a few outliers.

Figure 4 shows the results for study condition V10b, where, after 5 nights of extended sleep (10 h of TIB), subjects were challenged with 5 nights of 5 h of TIB per night, followed by 3 recovery nights of 8 h of TIB. Subjects consumed 200 mg of caffeine twice a day at 08:00 a.m. and 12:00 p.m. (noon) during the CSR phase. In this case, the group-average predictions yielded excellent agreement with the experimental data (RMSE 19 ms and fraction 100%, Figure 4a). Nevertheless, we did observe variability in the individualised predictions and the number of PVTs required to learn each subject. For example, while the individualised model learned subject #6 by CSR day C3 and yielded excellent agreement with the experimental data (RMSE 31 ms and fraction 98%, Figure 4b), the model only learned subject #8 after 3.5 days of CSR and yielded relatively low performance (RMSE 98 ms and fraction 43%, Figure 4d). In this case, the individualised model underpredicted alertness impairment during the last day of CSR and the first 2 days of recovery, where the experimental data were scattered.

We also assessed the ability of the individualised models to learn a subject's sleep-loss trait with a reduced set of PVT measurements.

We focused on the CSR conditions (V1b, V2a, V2b, V3a, and V10a; see Table 1) because they more closely resembled everyday sleep-deprivation conditions. Interestingly, we found that by using only two PVTs per day (taken at 10:00 a.m. and at ~6:30 p.m.) for 5 consecutive days, for a total of 10 PVTs, the individualised models were able to learn at least 70% of the learnable subjects in each study condition. For these subjects, the individualised models yielded RMSEs slightly larger (<11 ms) than those of the best-fit models. In particular, for two study conditions (V2b and V3a), the fraction of subjects learned with 10 PVTs was at least 80%.

DISCUSSION

To be useful, mathematical models must be able to accurately predict an individual's neurobehavioural performance as a function of time of day, sleep history, and caffeine consumption across a wide range of sleep and caffeine-consumption conditions. They must also be able to capture an individual's trait-like response to sleep deprivation, so as to account for the large between-subject variability (Rupp et al., 2012; Van Dongen, Baynard, Maislin, & Dinges, 2004). In this work, we validated the UMP, demonstrating its ability to adequately represent alertness impairment of a population, as well as of a specific individual, across a comprehensive set of 22 distinct conditions spanning the continuum of sleep loss and caffeine consumption.

Overall, the group-average UMP accurately predicted the mean PVT response for each sleep and caffeine condition, including seven caffeine-dosing schedules and 14 distinct sleep-deprivation conditions (Table 1). Quantitatively, we showed that the mean RMSE between the group-average predictions and the study-average PVT data across the 22 conditions and 301 unique subjects was 43 ms (range 15–74 ms), whereas the fraction of PVTs within the PIs was relatively high (80%; range 41%–100%), suggesting that in 80% of the cases the UMP predictions were indistinguishable from group-average PVT measurements. The fraction was <60% for only one study condition (V3a), which involved an extended sleep period during the baseline phase, followed by 7 nights of 3 h of TIB and a recovery phase (Table 4). In this case, the relatively low fraction (41%) is attributed to an abnormally small decrement in alertness impairment during CSR [in comparison to the decrement in similar sleep schedules in V2a (fraction = 69%) and V10a (fraction = 97%)], which resulted in an overprediction by the group-average model. The fractions for all other study conditions were >63%, and reached 100% for four conditions, indicating accurate predictions across a diverse set of sleep and caffeine schedules. To characterise any potential systematic error not captured by the RMSE or fraction metrics, we carried out an analysis of residuals (the difference between PVT measurements and predictions; see Supporting Information). The analysis showed that the residuals for the combined 22 conditions appeared normally distributed and without any systematic patterns other than an average overprediction of the measurements by 14 ms, which corresponds to 20% of the average half-width of the PIs. Thus, there was a positive bias in the predictions, but the bias was relatively small, confirming the validity of the group-average model. Although we observed obvious PVT

outliers in a number of subjects across the studies, our analysis included *all* reported data from each study.

We also assessed the ability of the UMP to learn the sleep-loss trait of each of the 301 unique individuals across the 22 study conditions. For the 81% of the subjects (244/301) deemed to be learnable (see Methods), we assessed model performance by comparing the individualised model predictions against each subject's PVT data (Table 4). Overall, the average RMSE across all predictions was 64 ms (average range per study 32–147 ms), where, on average, 71% of the PVTs of each subject in each session of each study condition fell within two SDs of the within-subject variability (59 ms for well-rested conditions; Khitrov et al., 2014). This suggests that, for these 244 subjects, in nearly three out of four PVTs we cannot distinguish between a single PVT measurement and the individualised model prediction. This is a conservative estimate because the within-subject variability is known to increase with sleep loss (Rupp et al., 2012). Assuming a 25% increase in within-subject variance (from 59 to 74 ms) during the sleep challenge phase of the studies would have increased the number of PVTs falling within this error bar to ~80%. To characterise any potential systematic error in the individualised model predictions, we also carried out an analysis of residuals (see Supporting Information). The analysis showed that the residuals for the combined 244 subjects in the 22 conditions appeared normally distributed and without systematic patterns other than an average over-prediction of the measurements by 6 ms, which corresponds to 10% of the half-width of the PIs. Thus, there was a positive bias in the individualised predictions, but the bias was relatively small, confirming the validity of the individualised models. As in the group-average predictions, our analysis used *all* reported data, including obvious outliers.

The UMP did not capture the sleep-loss traits of 57 (19%) of the 301 unique subjects. These subjects were not-learnable primarily because of the excessive variability in the PVT data (42 subjects) and because this variability slowed the learning process, not leaving sufficient data to assess the model predictions (15 subjects). To characterise the variability in the data used for validation between learnable and not-learnable subjects, we observed that the SD of the data for the not-learnable subjects was 270% larger. Notably, the variability was concentrated in a few studies. For example, 55% (or 23 subjects) of the 42 not-learnable subjects discussed above came from only two studies (V1 [15 subjects] and V9a [eight]), where the data showed excessive variability. In addition, the model does not have enough degrees of freedom to fit any one individual perfectly, even if we were to use all available data to fit the model to the data (i.e., to develop a best-fit model). In fact, developing individualised best-fit models for these 57 subjects and computing the performance metrics for the smallest of the last five PVTs, or 10% of the total number of PVTs available for each subject, yielded an average RMSE of 135 ms and an average fraction of 32%. In contrast, for the learnable 81% of the subjects, we obtained an average RMSE of 64 ms and an average fraction of 71%.

Because one of the motivations to develop the UMP was to bridge the continuum from CSR to TSD with a single model, we investigated whether there were differences in the performance of the models between the TSD studies (11 conditions) and the CSR studies (five conditions) in Table 4. For the group-average

predictions, the mean (SD) RMSE was 44 (21) ms and 36 (20) ms, and the average fraction of PVTs within the PIs was 80% (10%) and 81% (26%) for the TSD and CSR conditions, respectively. Similarly, for the individualised predictions, the mean (SD) RMSE was 72 (31) ms and 53 (4) ms and the average fraction of PVTs within the PIs was 64% (20%) and 82% (6%) for the TSD and CSR conditions, respectively. Based on two-sample *t* tests, there were no statistical differences at the 0.05 significance level in the performance metrics between the TSD and CSR conditions, for either the group-average or individualised model predictions, confirming one of the distinctive features of the UMP, the ability to bridge the continuum of sleep loss with a single model.

Although the overall results for the individualised model were similar to those of the group-average model, the latter cannot accurately predict each specific individual unless the alertness impairment is close to that of the “average” subject (Liu et al., 2017). To assess the benefit of model individualisation, we computed the RMSE between each subject's PVT data and the group-average model predictions for the same subset of PVT measurements used for validating the individualised models. The average RMSE across the 22 study conditions was 88 ms (versus 64 ms), a 38% increase in prediction error, demonstrating that model customisation produced more accurate predictions at the individual level. In general, the individualised model failed to accurately capture a subject's trait-like response to sleep loss when the subject's PVT data showed large variability, resulting in lower prediction accuracy, e.g., as for subject #8 in study condition V10b (Figure 4d).

We expected the number of PVTs required to individualise the model parameters to depend on the individual's sleep-loss phenotype, sleep schedule, caffeine consumption, as well as the frequency and timing of PVT sessions. For example, while it took on average 53 PVTs to learn the subjects in study condition V10a (placebo), it took only 36 PVTs in the caffeine arm of the study (V10b). To assess the effect of some of these factors, we plotted the cumulative distribution of the percentage of subjects in a given study condition learned by the model as a function of the number of PVTs needed to individualise the UMP parameters. However, we could only compare nine of the 12 studies in Figure 5 where the study had two arms that differed by only one factor (Table 1): V2 (baseline sleep of 8 versus 10 h of TIB), V3 (CSR versus TSD), and V6–V12 (caffeine versus placebo). As expected, the model was able to learn subjects with shorter baseline TIB duration (Figure 5b) and more acute sleep deprivation (Figure 5c) faster, consistent with previous results (Liu et al., 2017). We could not reach a conclusion on the comparison of caffeine versus placebo (Figure 5f–i), primarily because the model only learned some subjects after caffeine consumption. Nevertheless, we found variability in PVT data to be the chief factor driving the speed of model individualisation. As a result, because PVT measurements of resilient subjects have consistently low variability (see, e.g., Figure 1b–4b), the individualised model learned the traits of resilient subjects considerably faster than those of more vulnerable subjects.

Although the PVT is widely used to assess alertness in sleep studies, the task is rather tedious and time consuming. Therefore, to




FIGURE 5 Cumulative distribution of the percentage of subjects in a given study condition learned by the model as a function of the number of psychomotor vigilance test (PVT) measurements needed to individualise the model parameters. Nine panels represent studies with two conditions that differed by only one factor: (b) study V2 (baseline sleep of 8 versus 10 h of time in bed), (c) study V3 (chronic sleep restriction versus total sleep deprivation), and (f–l) studies V6–V12 (caffeine versus placebo). The dashed green curves and solid blue curves denote the results for study conditions “a” and “b,” respectively (see Table 1)

determine if it is possible to reduce this burden, we investigated whether the individualised models could learn the sleep-loss trait of an individual using only a subset of PVT measurements. Interestingly, for the five CSR conditions without caffeine consumption (V1b, V2a, V2b, V3a, and V10a; Table 1), at least 70% of the learnable subjects in each study condition required only 10 PVTs (taken at around 10:00 a.m. and 6:30 p.m. during 5 days of CSR) to generate models with similar performance to those obtained with the best-fit models. This represents nearly an 80% reduction in the average number of PVTs (48) available and used by the individualised models to learn the subjects' sleep-loss traits. This analysis suggests that taking two PVTs per day, one in the morning and one in the evening, for 5 consecutive

days of CSR conditions is sufficient to learn the trait-like response to sleep loss of most individuals.

While both caffeine intake and sleep opportunities were controlled in the three field studies in Table 1 (V6, V8, and V9), we investigated whether other factors not controlled in the studies could have influenced the PVT measurements and affected the models' performance. We did not observe significant differences in the performance metrics between models based on laboratory and field studies, for either the group-average or the individualised predictions (for the RMSEs, p values from two-sample t tests were 0.34 and 0.56, and for fractions they were 0.57 and 0.88, respectively). We did observe a large variability in the data of study condition V9a (a field study),

which precluded us from learning eight out of 15 subjects (Table 4). However, on the other arm of the study in condition V9b, a large variability was not an issue. We also observed a large variability in study V1, which was a laboratory study. These results support our modelling assumption that sleep and caffeine intake are the major factors influencing the prediction of alertness impairment.

Our study has limitations. The UMP was developed for healthy young adults without a history of sleep or neurological disorders and, therefore, the conclusions may be different for a heterogeneous and older population. Another possible limitation is that the UMP does not consider chronic caffeine consumption or withdrawal effects. Alertness enhancement for habitually high caffeine users may require larger caffeine doses than for habitually low caffeine users (Einoth et al., 2013). In addition, our results are based on PVT statistics, and it is unclear to what extent our findings can be applied to other neurocognitive performance measures. Finally, with the present approach, we were not able to individualise the model for 19% of the subjects. In theory, we could reduce this fraction by extending the model to account for additional individual characteristics or other factors that influence the PVT not included in the present model. However, adding new parameters to the model also increases the challenge of real-time parameter estimation.

Based on our analyses, we believe that real-world deployment of the UMP at the individualised level should follow two sequential phases of prospective, real-time validation: first in laboratory studies then in field studies. We started the first phase by integrating the UMP predictive engine into a smartphone to allow for prospective, real-time assessment. To this end, we created the *2B-Alert* app, which automatically learns the sleep-loss traits of individuals and predicts alertness impairment in real time as a function of sleep history, time of day, and caffeine consumption. To assess these capabilities, we recently performed a *prospective* study where 21 subjects used the *2B-Alert* app during a 62-h TSD laboratory challenge (study V5; Reifman et al., 2019). The results showed that the individualised models could capture the sleep-loss traits of the subjects in *real time* by using the first 36 h (12 PVTs) to learn the individuals, and then predicting their alertness for the last 24 h of the study. The average RMSE between the *2B-Alert* app predictions and the data was only 8 ms larger than that obtained with the best-fit model using all the data (54 versus 46 ms) (Reifman et al., 2019). For the same study, here we obtained a comparable average RMSE of 41 ms (Table 4), which is different because each individualised model assessed here was obtained with a different number of PVTs (see Methods). The next logical step is to assess individualised caffeine recommendations in a similar prospective, real-time laboratory study, paving the way for future field testing and the transition of individualised model predictions from the bench to the real world.

In summary, here we validated the group-average and individualised UMP models, demonstrating their ability to adequately predict alertness impairment at the population and individual-specific levels for 22 distinct conditions, spanning the continuum of sleep loss and caffeine consumption. Notably, we showed that the UMP was able to capture the sleep-loss trait of 81% of the subjects, and that the

individualised predictions for these subjects and the group-average predictions were indistinguishable from PVT measurements in nearly 80% of the cases, highlighting the benefits of these models as an integral element of fatigue-management tools (Reifman et al., 2019, 2022).

AUTHOR CONTRIBUTORSHIP

Jaques Reifman conceived the research. Nikolai V. Priezev and Francisco G. Vital-Lopez performed the computations. Nikolai V. Priezev and Jaques Reifman wrote the manuscript. All authors have reviewed the manuscript and approved the submitted version.

ACKNOWLEDGMENTS

This work was sponsored by the Military Operational Medicine Research Program of the US Army Medical Research and Development Command (USAMRDC), Fort Detrick, MD, and was supported by USAMRDC Contract No. W81XWH20C0031.

DATA AVAILABILITY STATEMENT

All data owned by the author's organization will be made available following a written request to the corresponding author, along with a summary of the planned research.

DISCLOSURE STATEMENT

This was not an industry-supported study. Francisco G. Vital-Lopez and Jaques Reifman receive royalties for the licensing of the *2B-Alert* technology to Integrated Safety Support. The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Army, the US Department of Defense, or The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. This paper has been approved for public release with unlimited distribution.

ORCID

Jaques Reifman  <https://orcid.org/0000-0001-7292-2029>

REFERENCES

- Belenky, G., Wesensten, N. J., Thorne, D. R., Thomas, M. L., Sing, H. C., Redmond, D. P., Russo, M. B., & Balkin, T. J. (2003). Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: A sleep dose-response study. *Journal of Sleep Research*, 12, 1–12. <https://doi.org/10.1046/j.1365-2869.2003.00337.x>
- Borbély, A. A., & Achermann, P. (1999). Sleep homeostasis and models of sleep regulation. *Journal of Biological Rhythms*, 14, 557–568. <https://doi.org/10.1177/074873099129000894>
- Einoth, S. J. L., et al. (2013). Caffeine as an attention enhancer: Reviewing existing assumptions. *Psychopharmacology*, 225, 251–274. <https://doi.org/10.1007/s00213-012-2917-4>
- Flynn-Evans, E. E., Kirkley, C., Young, M., Bathurst, N., Gregory, K., Vogelwohl, V., End, A., Hillenius, S., Pecena, Y., & Marquez, J. J. (2020). Changes in performance and bio-mathematical model performance predictions during 45 days of sleep restriction in a simulated space mission. *Scientific Reports*, 10, 15594. <https://doi.org/10.1038/s41598-020-71929-4>
- Hastie, T. J., Tibshirani, R. J., & Friedman, J. (2001). *The elements of statistical learning: Data mining, inference, and prediction*. Springer.

- Hilaire, M. A. S., Ruger, M., Fratelli, F., Hull, J. T., Phillips, A. J. K., & Lockley, S. W. (2017). Modeling neurocognitive decline and recovery during repeated cycles of extended sleep and chronic sleep deficiency. *Sleep*, 40, 1. <https://doi.org/10.1093/sleep/zsw009>
- Integrated Safety Support. *Smartphone Apps*. <https://integratedsafety.com.au/eclipse/smartphone-apps/#>. Accessed January 3, 2022.
- Kamimori, G. H., Johnson, D., Thorne, D., & Belenky, G. (2005). Multiple caffeine doses maintain vigilance during early morning operations. *Aviation, Space and Environmental Medicine*, 76, 1046–1050.
- Kamimori, G. H., McLellan, T. M., Tate, C. M., Voss, D. M., Niro, P., & Lieberman, H. R. (2015). Caffeine improves reaction time, vigilance and logical reasoning during extended periods with restricted opportunities for sleep. *Psychopharmacology*, 232, 2031–2042. <https://doi.org/10.1007/s00213-014-3834-5>
- Khitrov, M. Y., Laxminarayan, S., Thorsley, D., Ramakrishnan, S., Rajaraman, S., Wesensten, N. J., & Reifman, J. (2014). PC-PVT: A platform for psychomotor vigilance task testing, analysis, and prediction. *Behavior Research Methods*, 46, 140–147. <https://doi.org/10.3758/s13428-013-0339-9>
- Killgore, W. D., Rupp, T. L., Grugle, N. L., Reichardt, R. M., Lipizzi, E. L., & Balkin, T. J. (2008). Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. *Journal of Sleep Research*, 17, 309–321. <https://doi.org/10.1111/j.1365-2869.2008.00654.x>
- Landolt, H. P., Retey, J. V., & Adam, M. (2012). Reduced neurobehavioral impairment from sleep deprivation in older adults: Contribution of adenosinergic mechanisms. *Frontiers in Neurology*, 3, 62. <https://doi.org/10.3389/fneur.2012.00062>
- Liu, J., Ramakrishnan, S., Laxminarayan, S., Balkin, T. J., & Reifman, J. (2017). Real-time individualization of the unified model of performance. *Journal of Sleep Research*, 26, 820–831. <https://doi.org/10.1111/jsr.12535>
- Lo, J. C., Groeger, J. A., Santhi, N., Arbon, E. L., Lazar, A. S., Hasan, S., von Schantz, M., Archer, S. N., & Dijk, D. J. (2012). Effects of partial and acute total sleep deprivation on performance across cognitive domains, individuals and circadian phase. *PLoS One*, 7, e45987. <https://doi.org/10.1371/journal.pone.0045987>
- McLellan, T. M., Bell, D. G., & Kamimori, G. H. (2004). Caffeine improves physical performance during 24 h of active wakefulness. *Aviation, Space and Environmental Medicine*, 75, 666–672.
- McLellan, T. M., Kamimori, G. H., Bell, D. G., Smith, I. F., Johnson, D., & Belenky, G. (2005). Caffeine maintains vigilance and marksmanship in simulated urban operations with sleep deprivation. *Aviation, Space and Environmental Medicine*, 76, 39–45.
- Mitchell, D. C., Knight, C. A., Hockenberry, J., Teplansky, R., & Hartman, T. J. (2014). Beverage caffeine intakes in the U.S. *Food and Chemical Toxicology*, 63, 136–142. <https://doi.org/10.1016/j.fct.2013.10.042>
- Powell, D., Spencer, M. B., & Petrie, K. (2014). Comparison of in-flight measures with predictions of a bio-mathematical fatigue model. *Aviation, Space and Environmental Medicine*, 85, 1177–1184. <https://doi.org/10.3357/ASEM.3806.2014>
- Rajdev, P., Thorsley, D., Rajaraman, S., Rupp, T. L., Wesensten, N. J., Balkin, T. J., & Reifman, J. (2013). A unified mathematical model to quantify performance impairment for both chronic sleep restriction and total sleep deprivation. *Journal of Theoretical Biology*, 331, 66–77. <https://doi.org/10.1016/j.jtbi.2013.04.013>
- Ramakrishnan, S., Rajaraman, S., Laxminarayan, S., Wesensten, N. J., Kamimori, G. H., Balkin, T. J., & Reifman, J. (2013). A bio-mathematical model of the restoring effects of caffeine on cognitive performance during sleep deprivation. *Journal of Theoretical Biology*, 319, 23–33. <https://doi.org/10.1016/j.jtbi.2012.11.015>
- Ramakrishnan, S., Lu, W., Laxminarayan, S., Wesensten, N. J., Rupp, T. L., Balkin, T. J., & Reifman, J. (2015). Can a mathematical model predict an individual's trait-like response to both total and partial sleep loss? *Journal of Sleep Research*, 24, 262–269. <https://doi.org/10.1111/jsr.12272>
- Ramakrishnan, S., Wesensten, N. J., Balkin, T. J., & Reifman, J. (2016a). A unified model of performance: Validation of its predictions across different sleep/wake schedules. *Sleep*, 39, 249–262. <https://doi.org/10.5665/sleep.5358>
- Ramakrishnan, S., Wesensten, N. J., Kamimori, G. H., Moon, J. E., Balkin, T. J., & Reifman, J. (2016b). A unified model of performance for predicting the effects of sleep and caffeine. *Sleep*, 39, 1827–1841. <https://doi.org/10.5665/sleep.6164>
- Reifman, J., Ramakrishnan, S., Liu, J., Kapela, A., Doty, T. J., Balkin, T. J., Kumar, K., & Khitrov, M. Y. (2019). 2B-Alert App: A mobile application for realtime individualized prediction of alertness. *Journal of Sleep Research*, 28, e12725. <https://doi.org/10.1111/jsr.12725>
- Reifman, J., Kumar, K., Hartman, L., Frock, A., Doty, T. J., Balkin, T. J., Ramakrishnan, S., & Vital-Lopez, F. G. (2022). 2B-Alert Web 2.0, an open-access tool for predicting alertness and optimizing the benefits of caffeine: Utility study. *Journal of Medical Internet Research*, 24, e29595. <https://doi.org/10.2196/29595>
- Rétey, J. V., Adam, M., Gottselig, J. M., et al. (2006). Adenosinergic mechanisms contribute to individual differences in sleep deprivation-induced changes in neurobehavioral function and brain rhythmic activity. *Journal of Neuroscience*, 26, 10472–10479. <https://doi.org/10.1523/JNEUROSCI.1538-06.2006>
- Rupp, T. L., Wesensten, N. J., & Balkin, T. J. (2012). Trait-like vulnerability to total and partial sleep loss. *Sleep*, 35, 1163–1172. <https://doi.org/10.5665/sleep.2010>
- Rupp, T. L., Wesensten, N. J., Bliese, P. D., & Balkin, T. J. (2009). Banking sleep: realization of benefits during subsequent sleep restriction and recovery. *Sleep*, 32, 311–321. <https://doi.org/10.1093/sleep/32.3.311>
- So, C. J., Quartana, P. J., & Ratcliffe, R. H. (2016). Caffeine efficacy across a simulated 5-day work week with sleep restriction. *Sleep*, 39, A92.
- Van Dongen, H. P., Baynard, M. D., Maislin, G., & Dinges, D. F. (2004). Systematic interindividual differences in neurobehavioral impairment from sleep loss: Evidence of trait-like differential vulnerability. *Sleep*, 27, 423–433. <https://doi.org/10.1093/SLEEP/27.3.423>
- Vital-Lopez, F. G., Doty, T. J., & Reifman, J. (2021). Optimal sleep and work schedules to maximize alertness. *Sleep*, 44, 144. <https://doi.org/10.1093/sleep/zsab144>
- Wesensten, N. J., Belenky, G., Thorne, D. R., Kautz, M. A., & Balkin, T. J. (2004). Modafinil vs. caffeine: Effects on fatigue during sleep deprivation. *Aviation, Space and Environmental Medicine*, 75, 520–525.
- Wesensten, N. J., Killgore, W. D., & Balkin, T. J. (2005). Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. *Journal of Sleep Research*, 14, 255–266. <https://doi.org/10.1111/j.1365-2869.2005.00468.x>
- Wesensten, N. J., Reichardt, R. M., & Balkin, T. J. (2007). Ampakine (CX717) effects on performance and alertness during simulated night shift work. *Aviation, Space and Environmental Medicine*, 78, 937–943.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Priezev, N. V., Vital-Lopez, F. G., & Reifman, J. (2023). Assessment of the unified model of performance: accuracy of group-average and individualised alertness predictions. *Journal of Sleep Research*, 32(2), e13626. <https://doi.org/10.1111/jsr.13626>